Dengue vaccine to be ready by 2020’

 The Hindu
Chennai, December 20, 2017

Union Minister of State for Health Ashwini Kumar says several drugs set for clinical trials

India is currently working on vaccines to prevent dengue and the Phase 1 clinical trials for one of them is slated to be held in 2020, Ashwini Kumar Choubey, Minister of State for Health, told the Rajya Sabha on Tuesday.
In response to questions raised by another member T.K. Rajendran, Mr. Choubey said DSV4, the vaccine developed by The International Centre for Genetic Biotechnology (ICGEB)-Sun Pharma collaborative venture, is a recombinant vaccine on the Virus-Like Particles (VLP) platform with a tetravalent four-in-one VLP design; expressed in yeast, it elicits antibodies to all four DENV serotypes in a shorter schedule of 0, 1 and 2 months.
The vaccine is expected to move into Phase I clinical trials by 2020, Mr. Choubey said.
The other experiment involves the Panacea Dengue Vaccine, which is a cell culture-derived live attenuated, recombinant, freeze- dried, lyophilized tetravalent vaccine with the seed strain borrowed from the National Institute of Health (NIH), US.
The company has successfully completed preclinical toxicology studies.
The Drug Controller General India had granted permission to conduct clinical Phase I/II studies.
The Serum Institute of India is also developing a cell culture-derived live attenuated, recombinant, freeze-dried, lyophilized tetravalent vaccine with seed strain borrowed from the NIH. Preclinical toxicity study will be initiated soon.
The Minister said there were three global vaccines also currently under way. They are CYD-TDV or Dengvaxia of Sanofi Pasteur, a live attenuated vaccine made of non-structural proteins of YF17D.
The vaccine is recommended in three doses (0/6/12 months) at 9+ years of age and is marketed in more than 18 countries now. The TDV (Takeda) live attenuated vaccine is made from non-structural proteins of DENV2 and recommended in two doses (0/3 months) between 4 and 16 years of age. This vaccine will enter Phase III clinical trials in 2018. The TV003/TV005 (NIH & InstitutoBhutantan) live attenuated vaccine is made from non-structural proteins of DENV 1/3/4. It is recommended as one dose between 2 and 59 years of age. The vaccine will enter Phase III clinical trials in 2018, Mr. Choubey informed.
Providing data on the number of dengue cases reported over three years, he said there had been 225 deaths and around 1.50,482 cases reported till November 30, 2017.


Comments

Post a Comment

Popular posts from this blog

India Joins Russia in Voting Against West-Backed Move to Expand Powers of OPCW

The Wire: June 28, 2018 New Delhi: India voted against a UK-backed move that will allow the global chemical weapons watchdog to apportion blame for illegal attacks, criticising the decision to grant “unchecked powers” to the head of the group which could be used for “partisan” purposes. On Wednesday, more than two-thirds of the member states of the Organisation for the Prohibition of Chemical Weapons (OPCW) voted to authorise the international body to identify the perpetrators and sponsors of a chemical weapons attack. It also specifically called on the OPCW’s technical secretariat to begin work on identifying the perpetrators behind the use of chemical weapons in Syria. The draft decision, sponsored by 30 countries, was adopted at the fourth special session of the conference of the states parties to the Chemical Weapons Convention at the Hague, with 82 in favour and 24 negative votes. While Europe, the United States and their allies voted ‘yes’, there was strong oppo...
Read more

As financial insecurity rises in urban India, so does investment in insurance

Image
Scroll.in March 13, 2020 Urban Indians are becoming less confident about their financial security. Up to 58% of them fret over financial independence post retirement, which is a 4% increase from last year. An equal share of urban Indians worry about meeting their daily medical expenses and sustaining their current lifestyle once they stop working. The findings are part of a survey published by Delhi-based Max Life Insurance in association with London-based consultancy Kantar. The firms surveyed 7,014 respondents in 25 cities, including six metros, nine tier-1 cities, and 10 tier-2 cities, between December 2019 and January 2020. Source: Max Life Insurance via Quartz The trends Source: Max Life Insurance via Quartz Source: Max Life Insurance via Quartz Source: Max Life Insurance via Quartz A significant share of urban Indians also say their families will have no financial support in the event of the breadwinner’s death. In such a scenario, around 57% believe the family sav...
Read more

ED tracks Swiss Bank A/Cs of Agusta scamster

The Poineer February 10,2019 Rakesh K Singh The Enforcement Directorate (ED) has tracked a dozen Swiss bank accounts in the name of Rajiv Saxena, who is key accused in the Rs 3,600 crore AgustaWestland VVIP chopper scam. The ED has also found out accounts held by  his family members and associates where the kickbacks in the now scrapped deal were allegedly parked. Two bank accounts are in the name of Rajiv Saxena’s  associates Pankaj Jain and Sumita Jain who are also the authorised signatories. The  third is in the name of another associate Ajit Singh Bubber, but Rajiv and his family members are authorised signatories. The remaining nine accounts are largely owned and operated by Rajiv, his family members and associates. Rajiv Saxena was deported by the UAE authorities on January 30 and the ED formally arrested him the next day and a court later granted his remand to the agency. He is currently undergoing custodial interrogation by the ED. The agency had in 2017...
Read more